MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN

HER2-overexpressing breast cancers are characterized by frequent distant metastasis and often develop resistance after short-term effective treatment with the monoclonal antibody drug, trastuzumab. Here, we found that the oncogenic miRNA, miR-221, inhibited apoptosis, induced trastuzumab resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xingming, Bai, Wendong, Zhu, Huayu, Zhang, Xiao, Chen, Ying, Wang, Lei, Yang, Angang, Zhao, Jing, Jia, Lintao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163864/
https://www.ncbi.nlm.nih.gov/pubmed/24286315
http://dx.doi.org/10.5483/BMBRep.2014.47.5.165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163864/
https://www.ncbi.nlm.nih.gov/pubmed/24286315
http://dx.doi.org/10.5483/BMBRep.2014.47.5.165

Ejemplares similares